DMK Pharmaceuticals Corporation (DMKPQ)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Breakdown | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -25.9 Million | -37.78 Million | -20.9 Million | -19.88 Million | -32.65 Million | -15.13 Million |
| Net Income | -26.19 Million | -34.6 Million | -35.84 Million | -27.51 Million | -39 Million | -25.53 Million |
| Depreciation & Amortization | 1.46 Million | 1.42 Million | 2.33 Million | 2.96 Million | 3.09 Million | 3.06 Million |
| Deferred income taxes | - | - | - | - | -372.47 Thousand | -343.55 Thousand |
| Stock-based compensation | -340.27 Thousand | 1.98 Million | 4.1 Million | 5.86 Million | - | - |
| Change in working capital | -1.34 Million | -10.79 Million | 6.97 Million | -616.42 Thousand | -6.54 Million | 527.69 Thousand |
| Other non-cash items | 261.71 Thousand | 14.43 Million | 12.14 Million | 11.35 Million | 20.91 Million | 13.66 Million |
| Investing Cash Flow | 3.48 Million | 282.73 Thousand | -946.21 Thousand | -2.86 Million | -3.53 Million | -2.08 Million |
| Investments in PPE | -680.41 Thousand | -1.22 Million | -700.46 Thousand | -2.86 Million | -3.53 Million | -2.08 Million |
| Acquisitions | - | - | - | - | - | 1100.00 |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | 4.16 Million | 1.5 Million | -245.74 Thousand | - | - | - |
| Financing Cash Flow | 285 Thousand | 53.93 Million | 19.89 Million | 12.29 Million | 37.13 Million | 30.45 Million |
| Debt repayment | - | -7.61 Million | -3.19 Million | -496.79 Thousand | -487.9 Thousand | -2.33 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 285 Thousand | 48.41 Million | 16.79 Million | 12.78 Million | 37.61 Million | 32.78 Million |
| Other Financing Activities | -15 Thousand | -2.1 Million | -90.62 Thousand | -1.01 Million | - | - |
| Accounts receivables | -269.44 Thousand | -7.06 Million | 324.84 Thousand | -745.14 Thousand | -421.01 Thousand | -87.62 Thousand |
| Accounts payables | 3.93 Million | 1.9 Million | -388.37 Thousand | 574.51 Thousand | 846.12 Thousand | 587.15 Thousand |
| Inventory | -820.17 Thousand | -236.15 Thousand | -1.77 Million | 24.76 Thousand | -4.98 Million | -882.49 Thousand |
| Other working capital | -4.18 Million | -5.4 Million | 8.81 Million | -470.54 Thousand | -1.98 Million | 910.66 Thousand |
| Cash at beginning of period | 23.25 Million | 6.74 Million | 8.81 Million | 19.27 Million | 18.33 Million | 5.09 Million |
| Cash at end of period | 1.11 Million | 23.25 Million | 6.74 Million | 8.81 Million | 19.27 Million | 18.33 Million |
| Capital Expenditure | -680.41 Thousand | -1.22 Million | -700.46 Thousand | -2.86 Million | -3.53 Million | -2.08 Million |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -22.13 Million | 16.5 Million | -2.06 Million | -10.46 Million | 938.94 Thousand | 13.23 Million |
| Free Cash Flow | -26.58 Million | -39 Million | -21.6 Million | -22.75 Million | -36.19 Million | -17.22 Million |
| Breakdown | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 FY | 2022 Q4 | 2022 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -1.73 Million | -7 Million | -9.01 Million | -26.19 Million | -3.4 Million | -4.27 Million |
| Depreciation & Amortization | 2132.00 | 80.54 Thousand | 102.66 Thousand | 1.46 Million | 367.05 Thousand | 394.97 Thousand |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | -44.69 Thousand | 52.19 Thousand | 69.29 Thousand | -340.27 Thousand | -325.95 Thousand | - |
| Change in working capital | -1.31 Million | 1.67 Million | 4.95 Million | -1.34 Million | 861.98 Thousand | -3.55 Million |
| Other non-cash items | 707.42 Thousand | 1.65 Million | -789.34 Thousand | 261.71 Thousand | -384.12 Thousand | 2.2 Million |
| Investing Cash Flow | 1.76 Million | 138.29 Thousand | 841.77 Thousand | 3.48 Million | 155.3 Thousand | 779.22 Thousand |
| Investments in PPE | - | - | - | -680.41 Thousand | -91.49 Thousand | -207.75 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | 1.76 Million | 138.29 Thousand | 841.77 Thousand | 4.16 Million | 246.79 Thousand | 986.97 Thousand |
| Financing Cash Flow | 7.96 Million | 750.00 | 2.72 Million | 285 Thousand | - | 285 Thousand |
| Debt repayment | -7.09 Million | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 870.79 Thousand | 750.00 | 2.72 Million | 285 Thousand | - | 285 Thousand |
| Other Financing Activities | -912.75 Thousand | - | -275 Thousand | -15 Thousand | - | - |
| Accounts receivables | - | - | 1.05 Million | -269.44 Thousand | -697.91 Thousand | -1.58 Million |
| Accounts payables | -1.39 Million | 1.19 Million | 1.77 Million | 3.93 Million | 2.61 Million | 787.24 Thousand |
| Inventory | 1396.00 | - | 574.42 Thousand | -820.17 Thousand | -146.33 Thousand | -681.25 Thousand |
| Other working capital | 75.96 Thousand | 476.17 Thousand | 1.54 Million | -4.18 Million | -908.14 Thousand | -2.07 Million |
| Cash at beginning of period | 670.34 Thousand | 3.12 Million | 1.11 Million | 23.25 Million | 2.45 Million | 8.9 Million |
| Cash at end of period | 6.66 Million | 670.34 Thousand | 3.12 Million | 1.11 Million | 1.11 Million | 2.45 Million |
| Capital Expenditure | - | - | - | -680.41 Thousand | -91.49 Thousand | -207.75 Thousand |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 5.99 Million | -2.45 Million | 2.01 Million | -22.13 Million | -1.33 Million | -6.45 Million |
| Free Cash Flow | -3.73 Million | -2.56 Million | -1.54 Million | -26.58 Million | -1.61 Million | -7.7 Million |
4337
3917
ASPO
PANACEABIO
6301
8898